摘要
皮质类固醇常用于治疗炎症性肠病。 尽管它们可能非常有用，但必须牢记其潜在的不利影响。 如果可能，应避免使用这些药物的一种情况是围手术期设置。 如果患者在接受类固醇激素治疗的同时进行手术，那么感染和非感染性手术并发症的发生率将更高。 在多学科方法中应注意这一事实，该方法还应考虑其他因素，例如营养。
关键词: 皮质类固醇，手术，克罗恩病，溃疡性结肠炎，并发症，炎症性肠病。
[1]
Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn’s disease. Aliment Pharmacol Ther 2007; 26(3): 313-29.
[2]
Lichtenstein GR1, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
[3]
Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-63.
[4]
Wang AS1, Armstrong EJ, Armstrong AW. Corticosteroids and wound healing: clinical considerations in the perioperative period. Am J Surg 2013; 206: 410-7.
[http://dx.doi.org/10.1016/j.amjsurg.2012.11.018]
[http://dx.doi.org/10.1016/j.amjsurg.2012.11.018]
[5]
Eriksen TF1. Lassen CB, Gögenur I. Treatment with corticosteroids and the risk of anastomotic leakage following lower gastrointestinal surgery: a literature survey. Colorectal Dis 2014; 16: O154-60.
[http://dx.doi.org/10.1111/codi.12490]
[http://dx.doi.org/10.1111/codi.12490]
[6]
Agrawal A1, Durrani S, Leiper K, et al. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn’s disease. Clin Gastroenterol Hepatol 2005; 3(12): 1215-20.
[7]
Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc 2011; 86: 748-57.
[http://dx.doi.org/10.4065/mcp.2011.0074]
[http://dx.doi.org/10.4065/mcp.2011.0074]
[8]
Gionchetti P, Dignass A, Danese S, et al. Third European evidence-based consensus on the diagnosis and management of crohn’s disease 2016: part 2: surgical management and special situations. J Crohn’s Colitis 2017; 11: 135-49.
[http://dx.doi.org/10.1093/ecco-jcc/jjw169]
[http://dx.doi.org/10.1093/ecco-jcc/jjw169]
[9]
Bruewer M, Utech M, Rijcken EJ, et al. Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohńs disease. World J Surg 2003; 27: 1306-10.
[10]
Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008; 103: 2373-81.
[http://dx.doi.org/10.1111/j.1572-0241.2008.01942.x]
[http://dx.doi.org/10.1111/j.1572-0241.2008.01942.x]
[11]
Nguyen GC, Elnahas A, Jackson TD. The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease. J Crohn’s Colitis 2014; 8: 1661-7.
[http://dx.doi.org/10.1016/j.crohns.2014.07.007]
[http://dx.doi.org/10.1016/j.crohns.2014.07.007]
[12]
Kotze PG, Saab MP, Saab B, et al. Tumor necrosis factor alpha inhibitors did not influence postoperative morbidity after elective surgical resections in crohn’s disease. Dig Dis Sci 2017; 62: 456-64.
[http://dx.doi.org/10.1007/s10620-016-4400-2]
[http://dx.doi.org/10.1007/s10620-016-4400-2]
[13]
Ferrante M1, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15(7): 1062-70.
[http://dx.doi.org/10.1002/ibd.20863]
[http://dx.doi.org/10.1002/ibd.20863]
[14]
Zerbib P, Koriche D, Truant S, et al. Pre-operative management is associated with low rate of post-operative morbidity in penetrating Crohn’s disease. Aliment Pharmacol Ther 2010; 32: 459-65.
[http://dx.doi.org/10.1111/j.1365-2036.2010.04369.x]
[http://dx.doi.org/10.1111/j.1365-2036.2010.04369.x]
[15]
2015 European Society of Coloproctology collaborating group. Risk factors for unfavourable postoperative outcome in patients with Crohn’s disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO. Colorectal Dis 2017.
[http://dx.doi.org/10.1111/codi.13889]
[http://dx.doi.org/10.1111/codi.13889]
[16]
Spinelli A, Allocca M, Jovani M, Danese S. Review article: optimal preparation for surgery in Crohn’s disease. Aliment Pharmacol Ther 2014; 40: 1009-22.
[http://dx.doi.org/10.1111/apt.12947]
[http://dx.doi.org/10.1111/apt.12947]
[17]
Patel KV, Darakhshan AA, Griffin N, et al. Patient optimization for surgery relating to Crohn’s disease. Nat Rev Gastroenterol Hepatol 2016; 13: 707-19.
[http://dx.doi.org/10.1038/nrgastro.2016.158]
[http://dx.doi.org/10.1038/nrgastro.2016.158]
[18]
Scarpa M, Martinato M, Bertin E, et al. intestinal surgery for crohn’s disease: role of preoperative therapy in postoperative outcome. Dig Surg 2015; 32: 243-50.
[http://dx.doi.org/10.1159/000381885]
[http://dx.doi.org/10.1159/000381885]
[19]
Lamore RF 3rd, Hechenbleikner EM, Ha C, et al. Perioperative glucocorticoid prescribing habits in patients with inflammatory bowel disease: a call for standardization. JAMA Surg 2014; 149: 459-66.
[20]
Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis 2017; 11: 649-70.
[21]
Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management. J Crohn’s Colitis 2017; 11: 769-84.
[22]
Øresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohn’s Colitis 2015; 9: 4-25.
[23]
Gionchetti P, Dignass A, Danese S. magro f, rogler f, lakatos p. 3rd european evidence-based consensus on the diagnosis and management of crohn’s disease 2016: part 2: surgical management and special situations. J Crohn’s Colitis 2017; 11: 135-49.
Article Metrics
64
1